Impaired inhibitory effect of interleukin-10 on the balance between matrix metalloproteinase-9 and its inhibitor in mononuclear cells from hyperhomocysteinemic subjects

Stroke

Volumn 37, Issue 7, 2006, Pages 1731-1736

  Holven, Kirsten B ^a,b   Halvorsen, Bente ^b   Bjerkeli, Vigdis ^b   Damås, Jan Kristian ^b   Retterstøl, Kjetil ^a   Mørkrid, Lars ^a   Ose, Leiv ^a   Aukrust, Pål ^a,b   Nenseter, Marit S ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cytokines; Homocysteine; Interleukins; Risk factors

Indexed keywords

GELATINASE B; INTERLEUKIN 10; MATRIX METALLOPROTEINASE INHIBITOR; STAT3 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN RECEPTOR; JAK1 PROTEIN, HUMAN; JANUS KINASE 1; MESSENGER RNA; PROTEIN TYROSINE KINASE; STAT3 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; ATHEROGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; HYPERHOMOCYSTEINEMIA; MALE; MONONUCLEAR CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; ATHEROSCLEROSIS; BIOSYNTHESIS; BLOOD; CELL CULTURE; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING; RISK; SECRETION; SIGNAL TRANSDUCTION;

ADULT; ATHEROSCLEROSIS; CELLS, CULTURED; FEMALE; HUMANS; HYPERHOMOCYSTEINEMIA; INTERLEUKIN-10; JANUS KINASE 1; LEUKOCYTES, MONONUCLEAR; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-TYROSINE KINASES; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-10; RISK; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745936443     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000226465.84561.cb     Document Type: Article

References (33)

1. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325:1202-1206.
2. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. J Am Med Assoc. 2002;288:2015-2022.
3. Bautista LE, Arenas IA, Penuela A, Martinez LX. Total plasma homocysteine level and risk of cardiovascular disease: a meta-analysis of prospective cohort studies. J Clin Epidemiol. 2002;55:882-887.
4. Casas J, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke: evidence on a causal link from medelian randomization. Lancet. 2005;365:224-232.
5. Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, Ueland PM, Kvale G. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. J Am Med Assoc. 1995;274:1526-1533.
6. Kokame K, Kato H, Miyata T. Homocysteine-respondent genes in vascular endothelial cells identified by differential display analysis. GRP78/BiP and novel genes. J Biol Chem. 1996;271:29659-29665.
7. Upchurch GR Jr, Welch GN, Fabian AJ, Freedman JE, Johnson JL, Keaney JF Jr, Loscalzo J. Homocyst (e) ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem. 1997;272:17012-17017.
8. Holven KB, Aukrust P, Holm T, Ose L, Nenseter MS. Folic acid treatment reduces chemokine release from peripheral blood mononuclear cells in hyperhomocysteinemic subjects. Arteriscler Thromb Vasc Biol. 2002;22:699-703.
9. Malik N, Greenfield BW, Wahl AF, Kiener PA. Activation of human monocytes through CD40 induces matrix metalloproteinases. J Immunol. 1996;156:3952-3960.
10. George SJ. Tissue inhibitors of metalloproteinases and metalloproteinases in atherosclerosis. Curr Opin Lipidol. 1998;9:413-423.
11. Vaday GG, Hershkoviz R, Rahat MA, Lahat N, Cahalon L, Lider O. Fibronectin-bound TNF-alpha stimulates monocyte matrix metalloproteinase-9 expression and regulates chemotaxis. J Leukoc Biol. 2000;68:737-747.
12. Clark AW, Krekoski CA, Bou SS, Chapman KR. Edvards DR. Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett. 1997;238:53-56.
13. Heo JH, Lucero J, Abumiya T, Koziol JA. Copeland BR, del Zoppo GJ. Matrix metalloproteinases increase very early during experimental focal ischemia. J Cereb Blood Flow Metab. 1999;19:624-633.
14. Fukuda S, Fini CA. Mabuchi T, Koziol JA, Eggleston LL Jr, del Zoppo GJ. Focal cerebral ischemia induces active proteases that degrade microvascular matrix. Stroke. 2004;35:998-1004.
15. Wæhre T, Halvorsen B, Damås JK, Yndestad A, Brosstad F, Gullestad L, Kjekshus J, Frøland SS, Aukrust P. Inflammatory imbalance between IL-10 and TNF-α in unstable angina potential plaque stabilizing effects of IL-10. Eur J Clin Invest. 2002;32:803-810.
16. Seljeflot I, Hurlen M, Solheim S, Arnesen H. Serum levels of interleukin 10 are inversely related to future events in patients with acute myocardial infarction. J Thromb Haemost. 2004;2:350-352.
17. Pinderski Oslund LJ, Hedrick CC, Olvera T, Hagenbaugh A, Territo M, Berliner JA. Interleukin 10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol. 1999;119:2847-2853.
18. Mallat Z, Heymes C, Ohan J, Faggin E, Leseche G, Tedgui A. Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death. Arterioscler Thromb Vasc Biol. 1999:19;611-616.
19. Vila N, Castillo J, Davalos A, Esteve A, Planas AM. Chamorro A. Levels of anti-inflammatory cytokines and neurological worsening in acute ischemic stroke. Stroke. 2003;34:671-675.
20. Holven KB, Halvorsen B, Schulz H, Aukrust P, Ose L, Nenseter MS. Expression of matrix metalloproteinase-9 in mononuclear cells of hyperhomocysteinaemic subjects. Eur J Clin Invest. 2003;33:555-560.
21. Deleted in proof.
22. Damås JK, Eiken HG, Øie E, Bjerkeli V, Yndestad A, Ueland T, Tonnessen T, Geiran OR, Aass H, Simonsen S, Christensen G, Froland SS, Attramadal H, Gullestad L, Aukrust P.Myocardial expression of CC-and CXC chemokines and their receptors in human end-stage heart failure. Cardiovasc Res. 2000;47:778-787.
23. Scholz H, Sandberg W, Damås JK, Smith C, Andreassen AK, Gullestad L, Frøland SS, Yndestad A, Aukrust P, Halvorsen B. Enhanced plasma levels og LIGHT in unstable angina. Possible pathogenic role in foam cell formation and thrombosis. Circulation. 2005;112:2121-2129.
24. Holven KB, Scholz H, Halvorsen B, Aukrust P, Ose L, Nenseter MS. Hyperhomocysteinemic subjects have enhanced expression of lectin-like oxidized LDL receptor-1 in mononuclear cells. J Nutr. 2003;133:3588-3591.
25. Lang R, Patel D, Morris JJ, Rutschman RL, Murray PJ. Shaping gene expression in activated and resting primary macrophages by IL-10. J Immunol. 2002;169:2253-2263.
26. Rosell A, Alvarez-Sabin J, Arenilles JF. Rovira A, Delgado P, Fernandez-Cadenas I, Penalba A, Molina CA, Montaner J. A Matrix metalloproteinase Protein Array reveals a strong relation between MMP-9 and MMP-13 with diffusin-weighted image lesion increase in human stroke. Stroke. 2005;36:1415-1420.
27. Hofmann MA, Lalla E, Lu Y, Gleason MR, Wolf BM, Tanji N, Ferran LJ Jr, Kohl B, Rao V, Kisiel W, Stern DM, Schmidt AM. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest. 2001;107:675-683.
28. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, Ueno T, Sugi K, Imaizumi T. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol. 1998;32:368-372.
29. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, Meyer J, Cambien F, Tiret L; AtheroGene Investigators. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation. 2003;107:1579-1585.
30. Bugno M, Graeve L, Gatsios P, Koj A, Heinrich PC, Travis J, Kordula T. Identification of the interleukin-6/oncostatin M response element in the rat tissue inhibitor of metalloproteinases-1 (TIMP-1) promoter. Nucleic Acids Res. 1995;23:5041-5047.
31. Riley JK, Takeda K, Akira S, Schreiber RD. Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action. J Biol Chem. 1999;274:16513-16521.
32. Brown JC, Rosenquist TH, Monaghan DT. ERK2 activation by homocysteine in vascular smooth muscle cells. Biochem Biophys Res Commun. 1998;251:669-676.
33. Najib S, Sanchez-Margalet V. Homocysteine thiolactone inhibits insulin-stimulated DNA and protein synthesis: possible role of mitogen-activated protein kinase (MAPK), glycogen synthase kinase-3 (GSK-3) and p70 S6K phosphorylation. J Mol Endocrinol. 2005;34:119-126.